Blog & Resources Camargo Blog July 1st, 2013

FDA Goes Against Advisory Committee and Approves Low Dose Paroxentine for Hot Flashes

On 6/30/2013, FDA approved Noven Pharmaceuticals Brisdelle (paroxetine) for the treatment of vasomotor symptoms (hot flashes). This 505(b)(2) approval is notable since it is the first non-hormonal product product approved for this indication. But from a regulatory point of view, it is even more interesting – FDA went against a 10-4 Advisory Committee vote against approval. I have previously posted a comment on the Advisory Committee outcome. In that posting I noted that the FDA had stated that the proposed product failed to meet the endpoints spelled out in the guidance for drugs to treat this indication. The approval documents are not posted at this writing, so it is uncertain what the FDA reasoning might be. The FDA apparently heeded the concern of the Advisory Committee – the Noven product was approved with a boxed warning cautioning the user could face increased risk of suicide.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights